Growth and molecular interactions of the anti-EGFR antibody cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: new prospects in the treatment of triple-negative/basal-like breast cancer.

No abstract is available for this paper.

• Publication year

  2008

• Venue

  International Journal of Oncology

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.3892/IJO_00000106PMID 19020749
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Predicting protein-protein interactions in Arabidopsis thaliana through integration of orthology, gene ontology and co-expression

  2009cited by this paper
• Resistance to therapy caused by intragenic deletion in BRCA2

  2008cited by this paper
• Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers

  2008cited by this paper
• Bench to bedside: BRCA: From therapeutic target to therapeutic shield

  2008cited by this paper
• Clinical and pathologic aspects of basal-like breast cancers

  2008cited by this paper
• Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype.

  2008cited by this paper
• Basal-Like Breast Cancer Defined by Five Biomarkers Has Superior Prognostic Value than Triple-Negative Phenotype

  2008cited by this paper
• Cetuximab potentiates oxaliplatin cytotoxic effect through a defect in NER and DNA replication initiation

  2008cited by this paper
• Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance.

  2008cited by this paper
• An update of the mechanisms of resistance to EGFR-tyrosine kinase inhibitors in breast cancer: Gefitinib (Iressa) -induced changes in the expression and nucleo-cytoplasmic trafficking of HER-ligands (Review).

  2007influential reference
• Are triple-negative tumours and basal-like breast cancer synonymous?

  2007cited by this paper
• Triple Negative Breast Carcinoma and the Basal Phenotype: From Expression Profiling to Clinical Practice

  2007cited by this paper
• Triple negative tumours: a critical review

  2007cited by this paper
• BRCA1: cell cycle checkpoint, genetic instability, DNA damage response and cancer evolution

  2006cited by this paper
• In vivo and in vitro antitumor activity of oxaliplatin in combination with cetuximab in human colorectal tumor cell lines expressing different level of EGFR

  2006cited by this paper
• Deconstructing the molecular portrait of basal-like breast cancer.

  2006influential reference
• Treatment of HNSCC cell lines with the EGFR‐specific inhibitor cetuximab (Erbitux®) results in paradox phosphorylation of tyrosine 1173 in the receptor

  2006cited by this paper
• The MEK/MAPK pathway is involved in the resistance of breast cancer cells to the EGFR tyrosine kinase inhibitor gefitinib

  2006influential reference
• The role of BRCA1 in transcriptional regulation and cell cycle control

  2006cited by this paper
• The basal phenotype of BRCA1-related breast cancer: past, present and future.

  2006cited by this paper
• Basal-like breast cancer and the BRCA1 phenotype

  2006cited by this paper
• Trastuzumab in combination with heregulin-activated Her-2 (erbB-2) triggers a receptor-enhanced chemosensitivity effect in the absence of Her-2 overexpression.

  2006influential reference
• BRCA1 at the crossroad of multiple cellular pathways: approaches for therapeutic interventions

  2006cited by this paper
• New role for nuclear hormone receptors and coactivators in regulation of BRCA1-mediated DNA repair in breast cancer cell lines

  2005cited by this paper
• ERBB Receptors and Cancer: The Complexity of Targeted Inhibitors

  2005cited by this paper
• AlphaB-crystallin is a novel oncoprotein that predicts poor clinical outcome in breast cancer.

  2005cited by this paper
• The carboxyl-terminal of BRCA1 is required for subnuclear assembly of RAD51 after treatment with cisplatin but not ionizing radiation in human breast and ovarian cancer cells.

  2005cited by this paper
• Sequence-dependent antiproliferative effects of cytotoxic drugs and epidermal growth factor receptor inhibitors.

  2005cited by this paper
• ERBB receptors and cancer: the complexity of targeted inhibitors

  2005cited by this paper
• Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma

  2004influential reference
• Trafficking of the ErbB receptors and its influence on signaling.

  2003cited by this paper
• Disruption of the Fanconi anemia–BRCA pathway in cisplatin-sensitive ovarian tumors

  2003cited by this paper
• Mechanisms controlling EGF receptor endocytosis and degradation.

  2003cited by this paper
• Breast cancer classification and prognosis based on gene expression profiles from a population-based study

  2003cited by this paper
• Repeated observation of breast tumor subtypes in independent gene expression data sets

  2003cited by this paper
• Molecular mechanisms underlying endocytosis and sorting of ErbB receptor tyrosine kinases

  2001cited by this paper
• Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

  2001cited by this paper
• Untangling the ErbB signalling network

  2001cited by this paper
• Molecular portraits of human breast tumours

  2000cited by this paper
• The Breast Cancer Susceptibility Gene BRCA1 Is Required for Subnuclear Assembly of Rad51 and Survival following Treatment with the DNA Cross-linking Agent Cisplatin*

  2000cited by this paper
• Combination therapy with trastuzumab (Herceptin) and cisplatin for chemoresistant metastatic breast cancer: evidence for receptor-enhanced chemosensitivity.

  1999cited by this paper
• Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs

  1998cited by this paper
• Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment.

  1998cited by this paper
• BRCA1 up-regulation is associated with repair-mediated resistance to cis-diamminedichloroplatinum(II).

  1998cited by this paper
• Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells.

  1994cited by this paper
• p185c-erbB-2 signal enhances cisplatin-induced cytotoxicity in human breast carcinoma cells: association between an oncogenic receptor tyrosine kinase and drug-induced DNA repair.

  1994cited by this paper
• What is synergy?

  1989cited by this paper
• What is synergy?

  1989cited by this paper
• Monoclonal antibody against epidermal growth factor receptor is internalized without stimulating receptor phosphorylation.

  1986cited by this paper

• Targeting Receptor Tyrosine Kinases as a Novel Strategy for the Treatment of Triple-Negative Breast Cancer

  2024cites this paper
• EGFR as therapeutic target to develop new generation tyrosine kinase inhibitors against breast cancer: A critical review

  2024cites this paper
• Targeting the oral tumor microenvironment by nanoparticles: A review of progresses

  2023cites this paper
• Oligo-Fucoidan supplementation enhances the effect of Olaparib on preventing metastasis and recurrence of triple-negative breast cancer in mice

  2022cites this paper
• Inhibition of IκB Kinase Is a Potential Therapeutic Strategy to Circumvent Resistance to Epidermal Growth Factor Receptor Inhibition in Triple-Negative Breast Cancer Cells

  2022cites this paper
• Estrogens and Progestogens in Triple Negative Breast Cancer: Do They Harm?

  2021cites this paper
• Potentiating Therapeutic Effects of Epidermal Growth Factor Receptor Inhibition in Triple-Negative Breast Cancer

  2021cites this paper
• Antiproliferative effects of cetuximab on triple negative breast cancer cell line MDA-MB-231

  2020cites this paper
• Metal-based antibody drug conjugates. Potential and challenges in their application as targeted therapies in cancer.

  2019cites this paper
• SAR optimization studies on a novel series of 2-anilinopyrimidines as selective inhibitors against triple-negative breast cancer cell line MDA-MB-468.

  2019cites this paper
• EGFR Role in Cancer: A Potential Therapeutic Target

  2018cites this paper
• Production of a germline-humanized cetuximab scFv and evaluation of its activity in recognizing EGFR- overexpressing cancer cells

  2018cites this paper
• Eculizumab Dosing Regimen in Atypical HUS: Possibilities for Individualized Treatment

  2017cites this paper
• EphA2 receptor activation with ephrin-A1 ligand restores cetuximab efficacy in NRAS-mutant colorectal cancer cells.

  2017cites this paper
• Anti‐EGFR monoclonal antibodies enhance sensitivity to DNA‐damaging agents in BRCA1‐mutated and PTEN‐wild‐type triple‐negative breast cancer cells

  2017cites this paper
• Interactions Between Therapeutic Proteins and Small Molecules: The Shared Role of Perpetrators and Victims

  2017cites this paper
• PROGNOSTIC BIOMARKERS IN TRIPLE NEGATIVE BREAST CANCER AS A POTENTIAL TARGET FOR FUTURE DRUG DISCOVERY

  2017cites this paper
• Is a Five Marker Panel including Expression of Basal Markers ( EGFR and / or CK 5 / 6 ) compared to Three Marker Panel better in Predicting Prognosis in Molecular Subtypes of Breast Carcinoma ?

  2016cites this paper
• N0436 (Alliance): A Phase II Trial of Irinotecan With Cetuximab in Patients With Metastatic Breast Cancer Previously Exposed to Anthracycline and/or Taxane-Containing Therapy.

  2016cites this paper
• Critical Roles of EGFR Family Members in Breast Cancer and Breast Cancer Stem Cells: Targets for Therapy.

  2016cites this paper
• KRAS, EGFR AND PIK3CA mutation in triple negative breast carcinomas

  2016cites this paper
• Effect of Viola odorata Extract on Cell Survival of Triple Negative Breast Cancer MDA-MB-468 Cells

  2016cites this paper
• Role of tyrosine kinase-independent phosphorylation of EGFR with activating mutation in cisplatin-treated lung cancer cells.

  2015cites this paper
• Neurokinin-1 activation affects EGFR related signal transduction in triple negative breast cancer.

  2015cites this paper
• Combined Phosphoproteomics and Bioinformatics Strategy in Deciphering Drug Resistant Related Pathways in Triple Negative Breast Cancer

  2014cites this paper
• Small Activating RNA Restores the Activity of the Tumor Suppressor HIC-1 on Breast Cancer

  2014cites this paper
• Emerging EGFR antagonists for breast cancer

  2014cites this paper
• MiRNA-107 inhibits proliferation and migration by targeting CDK8 in breast cancer.

  2014cites this paper
• Deconstructing breast cancer heterogeneity: clinical implications for women with Basal-like tumors.

  2014cites this paper
• Breast Cancer Metastasis and Drug Resistance

  2013influential citation
• MiR-15a is underexpressed and inhibits the cell cycle by targeting CCNE1 in breast cancer.

  2013cites this paper
• FISETIN, A FLAVONOID, INDUCES CELL CYCLE ARREST AND APOPTOSIS IN HUMAN BREAST CANCER CELLS

  2013cites this paper
• The protein ERp57 contributes to EGF receptor signaling and internalization in MDA‐MB‐468 breast cancer cells

  2013influential citation
• MiR-15 a is underexpressed and inhibits the cell cycle by targeting CCNE 1 in breast cancer

  2013cites this paper
• The potential effect of triterpenoids in triple negative breast cancer

  2013cites this paper
• IGFBP-3 methylation-derived deficiency mediates the resistance to cisplatin through the activation of the IGFIR/Akt pathway in non-small cell lung cancer

  2013cites this paper
• Understanding Triple-Negative Breast Cancer

  2013cites this paper
• Nuclear EGFR as a molecular target in cancer.

  2013cites this paper
• The Potential Role of Nanotechnology in Therapeutic Approaches for Triple Negative Breast Cancer

  2013cites this paper
• 3,5-Disubstituted thiadiazine-2-thiones: New cell-cycle inhibitors

  2012cites this paper
• Platinum-Based Compounds for the Treatment of Metastatic Breast Cancer

  2012cites this paper
• ErbB2, EphrinB1, Src Kinase and PTPN13 Signaling Complex Regulates MAP Kinase Signaling in Human Cancers

  2012cites this paper
• Synthetic Lethal Interactions between EGFR and PARP Inhibition in Human Triple Negative Breast Cancer Cells

  2012cites this paper
• Pingyangmycin downregulates the expression of EGFR and enhances the effects of cetuximab on esophageal cancer cells and the xenograft in athymic mice

  2012cites this paper
• A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancer

  2012cites this paper
• Sphingosine kinase isoforms as a therapeutic target in endocrine therapy resistant luminal and basal-A breast cancer

  2012cites this paper
• Synergistic interactions of targeted therapy within signal transduction pathways

  2012cites this paper
• May metaplastic breast carcinomas be actually basal-like carcinoma? Further evidence study with its ultrastructure and survival analysis

  2011cites this paper
• 111In-labeled Nimotuzumab Modified with Nuclear Localization Sequences (NLS): An Auger Electron-emitting Radiotherapeutic Agent for EGFR-overexpressing and Trastuzumab-resistant Breast Cancer

  2011cites this paper
• Targeted therapies: EGFR inhibitors

  2011cites this paper
• Metastatic triple-negative breast cancer.

  2011cites this paper
• Molecular heterogeneity of triple-negative breast cancer and its clinical implications

  2011cites this paper
• Stem cell property epithelial‐to‐mesenchymal transition is a core transcriptional network for predicting cetuximab (Erbitux™) efficacy in KRAS wild‐type tumor cells

  2011cites this paper
• Discovery, synthesis, and investigation of the antitumor activity of novel piperazinylpyrimidine derivatives.

  2011cites this paper
• Immunohistochemical expression of epidermal growth factor receptor in breast cancer

  2011influential citation
• Lipid-rich carcinoma of the breast clinicopathologic analysis of 17 cases.

  2011cites this paper
• Syndecan-1 antigen, a promising new target for triple-negative breast cancer immuno-PET and radioimmunotherapy. A preclinical study on MDA-MB-468 xenograft tumors

  2011cites this paper
• The identification of biomarkers of chemotherapy resistance in breast cancer using comparative proteomics

  2011cites this paper
• Biomarkers of chemotherapy resistance in breast cancer identified by proteomics: current status.

  2010cites this paper
• Silencing Kinase-Interacting Stathmin Gene Enhances Erlotinib Sensitivity by Inhibiting Ser10 p27 Phosphorylation in Epidermal Growth Factor Receptor–Expressing Breast Cancer

  2010cites this paper
• Intratumoral expression level of epidermal growth factor receptor and cytokeratin 5/6 is significantly associated with nodal and distant metastases in patients with basal-like triple-negative breast carcinoma.

  2010cites this paper
• Characteristics of triple-negative breast cancer

  2010cites this paper
• Epidermal Growth Factor Receptor in Triple-Negative and Basal-Like Breast Cancer: Promising Clinical Target or Only a Marker?

  2010cites this paper
• Triple-negative/basal-like breast cancer: clinical, pathologic and molecular features

  2010cites this paper
• Triple negative breast cancer cell lines: one tool in the search for better treatment of triple negative breast cancer.

  2010cites this paper
• Triple negative breast cancer: from molecular portrait to therapeutic intervention.

  2010cites this paper
• Metformin regulates breast cancer stem cello ntogeny by transcriptional regulation of the epithelial-mesenchymal transition (EMT) status

  2010cites this paper
• Targeting tumour-initiating cells to improve the cure rates for triple-negative breast cancer

  2010cites this paper
• The Met oncogene and basal-like breast cancer: another culprit to watch out for?

  2010cites this paper
• Metformin and energy metabolism in breast cancer: from insulin physiology to tumour-initiating stem cells.

  2010cites this paper
• MUC1 regulates nuclear localization and function of the epidermal growth factor receptor

  2010cites this paper
• The anti-diabetic drug metformin suppresses the metastasis-associated protein CD24 in MDA-MB-468 triple-negative breast cancer cells.

  2010cites this paper
• Tyrosine Kinase Inhibitors in Triple Negative Breast Cancer

  2010influential citation
• DETERMINING THE ROLE OF MUC1 AND BETA-CATENIN ON THE EPIDERMAL GROWTH FACTOR RECEPTOR SIGNALING AND LOCALIZATION IN BREAST CANCER

  2010cites this paper
• Immunohistochemical expression and significance of epidermal growth factor receptor (EGFR) in breast cancer.

  2009cites this paper
• Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission.

  2009cites this paper
• ERalpha-negative and triple negative breast cancer: molecular features and potential therapeutic approaches.

  2009cites this paper
• What's positive about 'triple-negative' breast cancer?

  2009cites this paper
• Deconstructing Breast Cancer Heterogeneity: Clinical Implications for Women With Basal-Like Tumors

  year unknowncites this paper